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Backgrounds/Aims: Stem cell therapies for liver disease are being studied by many researchers worldwide, but scientific 
evidence to demonstrate the endocrinologic effects of implanted cells is insufficient, and it is unknown whether im-
planted cells can function as liver cells. Achieving angiogenesis, arguably the most important characteristic of the liver, 
is known to be quite difficult, and no practical attempts have been made to achieve this outcome. We carried out 
this study to observe the possibility of angiogenesis of implanted bio-artificial liver using scaffolds. Methods: This study 
used adipose tissue-derived stem cells that were collected from adult patients with liver diseases with conditions similar 
to the liver parenchyma. Specifically, microfilaments were used to create an artificial membrane and maintain the struc-
ture of an artificial organ. After scratching the stomach surface of severe combined immunocompromised (SCID) mice 
(n=4), artificial scaffolds with adipose tissue-derived stem cells and type I collagen were implanted. Expression levels 
of angiogenesis markers including vascular endothelial growth factor (VEGF), CD34, and CD105 were im-
munohistochemically assessed after 30 days. Results: Grossly, the artificial scaffolds showed adhesion to the stomach 
and surrounding organs; however, there was no evidence of angiogenesis within the scaffolds; and VEGF, CD34, and 
CD105 expressions were not detected after 30 days. Conclusions: Although implantation of cells into artificial scaffolds 
did not facilitate angiogenesis, the artificial scaffolds made with type I collagen helped maintain implanted cells, and 
surrounding tissue reactions were rare. Our findings indicate that type I collagen artificial scaffolds can be considered 
as a possible implantable biomaterial. (Korean J Hepatobiliary Pancreat Surg 2015;19:47-58)
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INTRODUCTION
There is an extreme worldwide lack of transplantable 
organs, and many patients are on waiting lists. According 
to 2013 data from the Korean Network for Organ Sharing 
(KONOS), there were 13,689 and 4,263 patients waiting 
for kidney and liver transplantations, respectively.1 These 
numbers are increasing by approximately 20% annually, 
but the numbers of donors remain flat. In 2013, just 1,351 
of the 4,263 patients received liver transplantation, but 
less than one-third were deceased donor transplants.1
This demand and supply mismatch of organs is a per-
sistent worldwide problem,2-4 and although many studies 
have been carried out to identify viable alternatives to de-
ceased donor organs, these projects remain in the early 
stages.5 Part of this effort is a liver support system that 
is largely categorized into two systems. The first is an ar-
tificial liver support system that mainly focuses on detox-
ification also known as the Molecular Absorbent 
Recirculating System (MARSTM), and the second is a 
bio-artificial liver support system that detoxifies and has 
synthetic and regulatory functions. Unfortunately, these 
systems are extremely expensive, and problems with the 
membrane and biocompatibility make it unlikely that 
these solutions will be clinically viable.6-8
Hepatocyte transplantation is another alternative. The 
donor’s hepatocytes are integrated into the recipient’s liver 
following their insertion into the portovenous system and 
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Fig. 1. Experimental model.
subsequent translocation to the hepatic sinusoids.9-11 This 
approach has been reported to be clinically effective in 
congenital metabolic diseases. For example, serum bilir-
ubin levels are reportedly decreased by 25-50% after hep-
atocyte transplantation in patients with Crigler-Najjar 
syndrome.12-16 However, the effect decreased with time, 
and patients eventually required whole liver transplantation 
due to hepatocyte graft failure after 4-48 months.
Regarding functional cell differentiation, there have 
been reports of endothelial cells producing dopamine,17 
pancreatic cells secreting insulin,18 and cells functioning 
as hepatocytes.19 In addition, cells differentiated from au-
tologous cells that function as hepatocytes have been 
transplanted into human recipients,20 but the lack of an-
giogenesis associated with these functional differentiated 
cells remains problematic.
Vasculogenesis and angiogenesis are unique processes. 
The former is the formation of primary capillary blood 
vessels from mesodermal cells that first differentiate into 
angioblasts and then endothelial cells.21 Angiogenesis in-
volves the sprouting of new vessels from existing 
vessels.21 This is a complex process that involves base-
ment membrane degradation and proliferation, migration, 
and endothelial cell tube formation. Angiogenesis is crit-
ical for the development and wound healing of normal tis-
sue, as well as ensuring adequate oxygen and nutrient sup-
plies to transplanted tissues.22
Angiogenesis is stimulated by hypoxia-inducible factors 
(HIFs) and the expression of many other signals including 
vascular endothelial growth factor (VEGF), platelet-derived 
growth factor (PDGF), and angiopoietin2 (Ang2).23 VEGF 
is a signaling peptide that facilitates angiogenesis,24 and 
immunohistochemical labeling of this protein has been used 
as a histological assessment tool.25-27 It increases the perme-
ability of endothelial cells and facilitates the creation of 
new vessels.28 When overexpressed, it can facilitate the 
development of cancer, atherosclerosis, rheumatic arthritis, 
diabetic retinopathy, and so on.29,30 
Other proteins such as CD31, CD34, CD105, and von 
Willebrand factor (vWF) also play important roles in 
angiogenesis. CD34 is a 110-kDa transmembrane glyco-
protein expressed in white blood cells, endothelial cells, 
and stem cells. It can also be found around the splenic 
marginal zone and in dendritic cells in vessels, nerves, 
sweat glands, and hair pouches.31,32 The function of CD34 
is not precisely known, but it is used to identify gastro-
intestinal stromal tumors and solitary fibrous tumors.33,34 
It is also used to assess the degree of angiogenesis.27,31-39 
CD105 (endoglin) is a 180-kDa transmembrane glyco-
protein, which is part of the transforming growth factor 
(TGF)- receptor complex. It controls angiogenesis by 
controlling cellular proliferation, differentiation, and 
migration.40 Unlike the VEGF or CD34, CD105 is weakly 
expressed in normal tissue and blood vessels but is strong-
ly expressed in tumors.40-42
Immunohistochemical labeling for the proteins men-
tioned above is helpful for assessing the degree of angio-
genesis in different model systems.31,35,37-39,43-45 In the 
present study, we collected adipose tissue-derived stem 
cells from adult patients with liver disease, placed them 
in artificial scaffolds, and implanted these scaffolds in se-
vere combined immunocompromised (SCID) mice to de-
termine whether they induced angiogenesis.
MATERIALS AND METHODS
Experimental model
We employed SCID mice as an experimental model to 
study angiogenesis in transplanted bio-artificial liver mod-
els (Fig. 1). Four scaffolds were transplanted considering 
possible errors and effectiveness. Adipose tissue-derived 
stem cells from human patients were implanted into the 
artificial scaffolds made of type I collagen, and the scaf-
folds were implanted into the stomach surface of SCID 
mice. Tissues attached to and near the scaffolds were ana-
lyzed 30 days after implantation, which is reportedly a 
sufficient period of time for adequate angiogenesis.46,47 
The tissue was processed into frozen sections, and im-
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Fig. 2. Schematic presentation 
and a photograph of the artifi-
cial scaffold model.
munohistochemistry labeling was performed to examine 
the expression of different angiogenesis markers.
Artificial scaffold production
Artificial scaffolds were comprised of adipose tissue-de-
rived stem cells and type I collagen. Adult adipose cells 
were obtained from abdominal subcutaneous fat acquired 
during liver tumor resection from consenting patients, and 
the type I collagen was from pig skin. Harvest of tissues 
was performed under anesthesia according to procedures 
approved by the Institutional Review Board (IRB, 
4-2013-0757) of Yonsei University Hospital, Korea. Type 
I collagen is the most abundant collagen in the human 
body, and it is a constituent of the extracellular matrix 
of internal organs such as the liver and spleen. Previous 
studies have shown that angiogenesis occurs through for-
eign body reaction;46 therefore, type I collagen was consid-
ered the perfect material for artificial scaffolds in this ex-
perimental model. The model for the artificial scaffold was 
supplied by a Nanotechnology Laboratory at Yonsei 
University. An illustration of the artificial scaffold model 
is shown in Fig. 2.
Artificial scaffold implantation into SCID mice
The 12-week old male SCID mice (Charles River 
Laboratory, MA, USA) weighing ~20 g were used for the 
experiment. The study was carried out after receiving ap-
proval from the laboratory animal rule committee (animal 
experiment protocol number 2013-0346). Artificial scaf-
fold implantation proceeded as follows. Anesthesia was 
induced by placing the animal in an inhalation chambers 
(RC2-rodent circuit controller, VetEquip, CA, USA) at in-
halation level 4, and anesthesia was maintained at level 
1.5-2 by placing an inhalation anesthetic tube near the an-
imal’s mouth. Under anesthesia, hair around the abdomen 
was removed, and the incision site at the left lateral decu-
bitus position was disinfected with betadine. After making 
an incision in the subcostal area of the abdominal wall 
with surgical scissors, forceps were used to expose the 
stomach. Silicon tubes were used to scratch the stomach’s 
surface, and the scaffolds were placed near the scratch. 
Vicryl 5-0 was used to fix the scaffolds by the fundus 
and pylorus of the stomach. The fixed artificial scaffolds 
were pressed into the abdominal cavity using cotton 
swabs, and the abdominal wall was sutured layer by layer 
using Vicryl 4-0. The anesthetic level was lowered during 
suturing to ensure a fast recovery of consciousness. The 
suture site was closely checked for 2-3 days after surgery.
Tissue processing
The specimens including the artificial scaffolds were 
removed 30 days after implantation to search for evidence 
of angiogenesis. They were immediately frozen after the 
mice were sacrificed. 12-m thick tissue slices were proc-
essed from frozen blocks of tissue. The slides were 
stained with hematoxylin and eosin (H&E) to observe the 
general characteristics of the artificial scaffolds. To block 
endogenous peroxidase, the slides were immersed in 0.3% 
H2O2 solution for 5-10 minutes and then washed for 5 mi-
nutes in distilled water. Next, they were stained with hem-
atoxylin for 5 minutes, washed with distilled water three 
times, washed with phosphate-buffered saline (PBS), im-
mersed in ammonia for 1 minute, washed with distilled 
water 3 times, and immersed in eosin for 5 minutes. After 
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Fig. 3. Adhesion of artificial scaffold to surrounding organs 30 days after implantation into SCID mice. (A) View of internal 
organs after opening the mouse abdomen. (B) The artificial scaffold (black arrow) was exposed with surgical forceps. The omen-
tum was covering the artificial scaffold.
Table 1. Antibodies used for immunohistochemistry*













*All antibodies were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA)
2 minutes in 80% ethanol, 2 minutes in 100% ethanol, 
and 2 minutes in xylene, the slides were cover-slipped 
with Permount solution and observed under a light micro-
scope (BX51, Olympus, Tokyo, Japan).
Known angiogenesis biomarkers (VEGF, CD34, and 
CD105) were immunohistochemically assessed. The frozen 
sections containing the artificial scaffolds and surrounding 
tissue were fixed for 5-10 minutes. To block endogenous 
peroxidase, the frozen sections were immersed in 0.3% hy-
drogen peroxide solution for 5-10 minutes and washed with 
distilled water for 5 minutes. Afterward, the blocks were 
placed a moist box and incubated at 4°C for a day with 
one of three primary antibodies directed against CD34, 
CD105, or VEGF (Table 1). Next, the sections were washed 
three times with PBS for 5 minutes each. Based on the 
visualization system instructions, the sections were in-
cubated with secondary antibodies including anti-rabbit 
IgG (HRP) (sc-2749, Santa Cruz, CA, USA) and anti goat 
IgG (HRP) (sc-2741, Santa Cruz, CA, USA) at room tem-
perature for 2 hours and then washed with PBS four times 
for 5 minutes each. The 1 : 250 diluted streptoavidin 
(DAKO, Glostrup, Denmark) reaction was carried out for 
more than 30 minutes, and then the blocks were washed 
with phosphate buffer saline (PBS) three times for 5 mi-
nutes each. Afterwards, the sections were chemically 
stained with the brown water-soluble dye diaminobenzidine 
(Vectorlabs, CA , USA) After washing with distilled water, 
the sections were incubated with hematoxylin for 
counterstaining. After a final wash in flowing distilled wa-
ter, the slides were immersed for 10 minutes in PBS. For 
dehydration and mounting, the blocks were immersed in 
95% alcohol for 2 minutes followed by xylene for 2 
minutes. The slides were then cover-slipped with Permount 
solution and examined under a microscope.
RESULTS
Gross findings
The gross findings in mice that were sacrificed and dis-
sected 30 days after artificial scaffold implantation are 
shown in Fig. 3. The artificial scaffolds were covered with 
the omentum and adhered to the fundus and pylorus su-
ture areas, as well as to the surrounding organs.
H&E staining
We observed the H&E-stained artificial scaffolds under 
low magnification to assess their overall appearance. Fig. 
4 shows collagen surrounding the scaffold that contained 
adipose tissue-derived stem cells. The collagen membrane 
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Fig. 4. H&E-stained images of the artificial scaffold material processed 30 days after implantation into SCID mice. Red eosin
stain showed the artificial collagen scaffold. Black arrows indicate where the scaffold was sutured to the mouse stomach.
was disrupted where the scaffold was sutured to fix it to 
the pylorus and fundus, and this membrane linked the arti-
ficial scaffold and the stomach.
We next observed the H&E-stained artificial scaffolds 
under high magnification to better assess its characteristics 
(Figs. 5, 6). The basement membrane surrounding the out-
er side of the artificial scaffold contained eosin-stained 
collagen without nuclei (Fig. 5), and we also observed 
hematoxylin-stained adipose tissue-derived stem cells 
within the artificial scaffold (Fig. 6).
Immunohistochemistry with VEGF, CD34, CD105
VEGF-labeled slides showed brown staining starting 
from the membrane of the artificial scaffold (Fig. 7A, B), 
but there was no evidence of endothelial cells or vascular 
structure at ×200 magnification. Although collagen was 
stained brown by diaminobenzidine, the inside of the cells 
were not positive for VEGF (Fig. 7E, F).
The inside and outside of the artificial membrane were 
assessed under high magnification to view cell shapes and 
differences in VEGF immunohistochemistry. Mouse omen-
tum cells were observed outside the scaffold, and there was 
no positive staining for VEGF (Fig. 7E). The inside of the 
artificial scaffold contained hematoxylin-stained adipose tis-
sue-derived stem cells and diaminobenzidine-stained colla-
gen but was negative for VEGF (Fig. 7F).
CD34-labeled slides also showed progressive brown 
stain starting from the membrane of the artificial scaffold 
(Fig. 8A, B), but again there was no sign of endothelial 
cells or vascular structures at ×200 magnification, and the 
inside of cells were negative for CD34 expression (Fig. 
8D, E). Both the inside and outside of the artificial scaffold 
were checked under high magnification in order to see the 
cell shape and difference in CD34 immunohistochemistry 
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Fig. 5. H&E-stained collagen of the artificial scaffold 30 days after implantation into SCID mice. The area in the black circle
(A) is magnified in (B-D). (D) The ×200 magnification shows the lack of nuclei in the red eosin-stained collagen surrounding
the artificial scaffold.
staining. Mouse omentum cells were observed outside the 
scaffold, and there was no positive staining for CD34 (Fig. 
8E). The inside of the artificial scaffold contained hematox-
ylin-stained adipose tissue-derived stem cells and dia-
minobenzidine-stained collagen but was negative for CD34 
(Fig. 8F).
The CD105 immunohistochemistry stained slide also 
showed progressive brown staining starting from the 
membrane of the artificial scaffold (Fig. 9A, B). There 
were no endothelial cells or vascular structures at ×200 
magnification, and the inside of the scaffold contained on-
ly stained collagen and was negative for CD105. Mouse 
omentum cells were observed outside the scaffold, and 
there was no positive staining for CD105 (Fig. 9E). On 
the other hand, the inside of the artificial scaffold con-
tained hematoxylin-stained adipose tissue-derived stem 
cells and diaminobenzidine-stained collagen but was neg-
ative for CD105 (Fig. 9F). Microscopic observation failed 
to reveal any endothelial cells or vascular structures within 
the artificial scaffolds. Although diaminobenzidine-stained 
brown collagen was visible inside the scaffolds, the three 
angiogenesis markers were not expressed.
DISCUSSION
In the past 20 years, most tissue engineering projects 
have employed thin structures such as skin or vesical 
arteries.48-50 Manufacturing thick tissues such as muscle, 
liver, and kidney on scaffolds was not considered possible 
due to insufficient diffusion of oxygen and nutrients.51 To 
overcome this problem, the pig liver experimental model 
was developed by removing most of the cells and only 
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Fig. 6. Magnification of the inner side of the H&E-stained artificial scaffold 30 days after implantation into SCID mice. The
area in the black circle (A) is magnified in (B-D). (D) The ×200 magnification shows eosin-stained collagen and hematox-
ylin-stained adipose tissue-derived stem cells within the artificial scaffold.
leaving the vessels with mechanical perfusion. Still, micro-
filaments and microtubules were damaged in the process.52
In the present study, we designed an experimental mod-
el under the assumption that vessels from the omentum 
will grow into the artificial scaffolds implanted onto the 
vessel-rich mouse stomach. In general, active liver re-
generation occurs for 7 days after liver resection in mice, 
and most show regeneration within a month.53 Previous 
studies reported that 30 days is a sufficient period of time 
for angiogenesis to occur. Therefore, we carried per-
formed immunohistochemical labeling 1 month after arti-
ficial scaffold implantation. We expected to observe an-
giogenesis in the artificial scaffolds, but light microscopy 
of H&E-stained and antibody-labeled sections failed to re-
veal any evidence of angiogenesis.
There were diaminobenzidine-stained brown regions in-
dicating that there could be transport of materials involved 
in angiogenesis from outside the artificial scaffold to 
inside. Specifically, the suture sites where the artificial 
scaffolds were fixed onto the mice appeared to contain 
connecting tracts. However, if there was angiogenesis 
from outside the artificial scaffolds, there would be evi-
dence of endothelial cells or tubular structures inside the 
scaffolds, and these changes were not observed. In addi-
tion, only collagen was stained by diaminobenzidine; there 
was no evidence of angiogenesis marker expression.
There are several possible reasons why we were unable 
to find evidences of angiogenesis markers. First, previous 
studies used 12 weeks old C57bl/6 male mice, whereas 
we used SCID mice to prevent a reaction to the implanted 
adipose-derived stem cells. While our animal model choice 
might have helped maintain the adipose-derived stem cells 
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Fig. 7. A VEGF-stained artificial scaffold processed 30 days after implantation into SCID mice. The area in the black circle 
(A) is magnified. (D) ×100 and (F) ×200 magnifications of the area in the black dotted circle shown in (B). The cells inside 
the artificial scaffold include hematoxylin-stained adipose tissue-derived stem cells and diaminobenzidine-stained collagen. (C) 
×100 magnification and (E) ×200 magnification of the area in the black circle shown in (B). The outside of the artificial scaffold
contained mouse omentum cells with no collagen. There was no endothelial or vascular structure or VEGF expression.
within the artificial scaffolds, it also could have been an 
obstacle preventing foreign body reaction and angiogenesis. 
Secondly, it is possible that the type I collagen scaffolds 
were not appropriate for inducing angiogenesis. But as van 
Amerongen et al. reported, angiogenesis occurred through 
foreign body reaction 7 days after the implantation of type 
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Fig. 8. A CD34-stained artificial scaffold processed 30 days after implantation into SCID. The area in the black circle (A) is 
magnified. (D) ×100 and (F) ×200 magnifications of the area in the black dotted circle area (B). The cells inside the artificial
scaffold include hematoxylin-stained adipose tissue-derived stem cells and diaminobenzidine-stained collagen. (C) ×100 magnifi-
cation and (E) ×200 magnification of the area in the black circle shown in (B). The outside of the artificial scaffold contained
mouse omentum cells with no collagen. There was no endothelial or vascular structure or CD34 expression.
I collagen into mice.46 Thirdly, our time points may have 
been too short, even though previous studies have shown 
that angiogenesis starts as early as 7 days after implantation 
and is clearly observed within 14 and 30 days.46,47 For a 
more appropriate comparison, it would have been better 
to have a comparison group of scaffold removal at 90 or 
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Fig. 9. A CD105-stained artificial scaffold processed 30 days after implantation into SCID. The area in the black circle (A)
is magnified. (D) ×100 and (F) ×200 magnifications of the area in the black dotted circle area (B). The cells inside the artificial
scaffold include hematoxylin-stained adipose tissue-derived stem cells and diaminobenzidine-stained collagen. (C) ×100 magnifi-
cation and (E) ×200 magnification of the area in the black circle shown in (B). The outside of the artificial scaffold contained
mouse omentum cells with no collagen. There was no endothelial or vascular structure or CD105 expression.
180 days.
If our second presumption is correct, it would indicate 
that artificial scaffolds made with type I collagen do not 
elicit sufficient tissue reaction. Although there might be 
adhesion to surrounding tissue, the implanted cells are 
maintained without angiogenesis, and this suggests that 
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type I collagen artificial scaffolds are an acceptable bio-
material for transplantation. Additional experiments on 
normal mice are needed to provide additional support for 
this theory.
In conclusion, there was no evidence of angiogenesis 
in the artificial scaffolds comprised of type I collagen 30 
days after implantation. Similarly, we did not observe en-
dothelial cells or angiogenesis markers. Although the re-
sults were negative, they do indicate that such scaffolds 
could be useful as a new biomaterial. Scaffolds made with 
type I collagen induced minimal tissue reactions and 
could maintain implanted cells. Additional research is 
needed to assess their utility in transplantation.
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